WO2025172917 - HETEROCYCLIC COMPOUNDS AS P300 DEGRADERS
National phase entry is expected:
Publication Number
WO/2025/172917
Publication Date
21.08.2025
International Application No.
PCT/IB2025/051599
International Filing Date
14.02.2025
Title **
[English]
HETEROCYCLIC COMPOUNDS AS P300 DEGRADERS
[French]
COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'AGENTS DE DÉGRADATION DE P300
Applicants **
AURIGENE ONCOLOGY LIMITED
Inventors
ABBINENI, Chandrasekhar
SAMAJDAR, Susanta
TALLURI, Krishna Chaitanya
Priority Data
202441011166
17.02.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3759 | |
| EPO | Filing, Examination, Granting | 22070 | |
| Japan | Filing, Examination, Granting | 2718 | |
| South Korea | Filing, Examination, Granting | 3173 | |
| USA | Filing, Examination, Granting | 10040 |
Total:
41,760
Contact Us
Abstract[English]
The present disclosure provides heterocyclic compounds of formula (I), a pharmaceutically acceptable salt thereof, a solvate thereof or an isomer thereof as protein degraders. These compounds are useful in the treatment and/or prevention of diseases and/or disorders responsive to the degradation of target protein. Compounds of the present disclosure are especially useful for treating cancer, autoimmune, inflammatory, and neurodegenerative diseases and disorders. The present disclosure also provides processes for preparation of the compounds and pharmaceutical formulations comprising at least one of the compounds of formula (I) or a pharmaceutically acceptable salt, a solvate or an isomer thereof.[French]
La présente divulgation concerne des composés hétérocycliques de formule (I), un sel pharmaceutiquement acceptable de ceux-ci, un solvate de ceux-ci ou un isomère de ceux-ci en tant qu'agents de dégradation de protéines. Ces composés sont utiles dans le traitement et/ou la prévention de maladies et/ou de troubles sensibles à la dégradation d'une protéine cible. Les composés de la présente divulgation sont particulièrement utiles pour le traitement du cancer, de maladies et de troubles auto-immuns, inflammatoires et neurodégénératifs. La présente divulgation concerne également des procédés de préparation des composés et des formulations pharmaceutiques comprenant au moins l'un des composés de formule (I) ou un sel pharmaceutiquement acceptable, un solvate ou un isomère de ceux-ci.